Cardiac Safety Service | NEXEL


 NEXEL Co., Ltd. provides leading technologies in the medical industry in South Korea. And, its products are designed to meet the needs of researchers, clinicians, and patients. Also, they are

designed to be easy to use and provide accurate results. They are committed to providing their customers with the best possible products and services. NEXEL is dedicated to providing its customers with high-quality products and services. Its mission is to develop new solutions that enhance patient care and outcomes. Its team is committed to creating products that are safe, effective, and easy to use.

NEXCEL is always ready to produce new treatments that can improve the lives of patients suffering from severe diseases. It is committed to providing innovative treatments that are safe, effective, and affordable. Its mission is to discover and develop therapies that can make a significant difference in patients' lives. NEXEL is also working on developing treatments for cancer and autoimmune diseases. It is dedicated to providing only the best.

NEXEL's NeXST (Cardiac Safety Service)

NEXEL’s NeXST cardiac safety service aims to aid its collaborators to make efficient decisions for their drug development programs. Although current safety guidelines have successfully eliminated hERG-related risk issues. There are many concerns over the accuracy of the assay as hERG-block does not always equate to QT prolongation in patients. Many other ion channels are involved, as well as calcium handling or contraction-related, not covered at all by the hERG assay. NEXEL is a member of the HESI CiPA working group and is currently participating in the ICH guideline revision making novel assays including iPS-Cardiomyocytes mandatory to preclinical toxicity testing. NEXEL's integrated cardiac safety platform has been extensively validated to provide accurate results based on the most recent standards.

If you are looking for cardiac safety service, you can find it at NEXEL.

Click here to contact NEXEL.

View more: Cardiac Safety Service

 

Comments

Post a Comment

Popular posts from this blog

iPSC Derived Cardiomyocytes and 3D Tissue Contractility Analysis | NEXEL

Image
NEXEL Co., Ltd. is committed to becoming a world-class biotech company. Its aim is to develop innovative new therapies to help patients and provide tools for researchers to boost their projects. Thus, they will create value for the investors, fellow researchers, and the world to make a better place.   NEXEL is a world leader in iPSC (induced pluripotent stem cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS derived cells which mimic actual human functionality. Furthermore, they are investing its expertise into the discovery and development of new drug candidates based on proteins and peptides derivations from stem cell technology.  NEXEL iPSC Derived Cardiomyocytes   NEXEL strives to provide high quality human cardiomyocytes from human induced pluripotent stem (iPS) cells using optimized proprietary protocols. The cardiosight-S is a highly pure...
Read more

3D Tissue Contractility Analysis | NEXEL

Image
  NEXEL Co., Ltd. is dedicated to developing world-class technologies and products that will improve the lives of patients and researchers. They are committed to providing their customers with high-quality products and services. They strive to be a biotechnology leader and a dependable partner for their customers. NEXEL is dedicated to providing its customers with high-quality products and services. Its mission is to create innovative solutions that improve patient care and outcomes. Its team is innovative to developing products that are safe, effective, and simple to use. It is always ready to produce the development of new treatments that can improve the lives of patients suffering from serious diseases. Its mission is to discover and develop therapies that can make a significant difference in patients' lives. NEXEL is also working on developing treatments for cancer and autoimmune diseases. It is dedicated to providing only the best. NEXEL's Mantarray (3D Tissue Co...
Read more

Korean iPSC Derived Cell Provider with New Discovery and Development | NEXEL

Image
NEXEL Co., Ltd. aspires to be a world-class biotech company. Its goal is to create innovative new therapies to help patients while also providing tools for researchers to help them with their projects. As a result, they will create value for investors, fellow researchers, and the world in order to make it a better place. As the first Korean company to licence iPS technology, NEXEL has established a new paradigm in the field of in vitro toxicity through the successful commercialization of iPS derived cells that mimic actual human functionality. In addition, they are putting their expertise to work in the discovery and development of new drug candidates based on proteins and peptides derived from stem cell technology. Their team is made up of talented people who share passion for innovation and high scientific standards. They are supported by invaluable collaborators from the academic and clinical communities.   Korean iPSC Derived Cell Provider NEXEL uses optimised proprietary proto...
Read more